...and next year Vertex will be able to provide 'breakthrough' treatment for the majority of CF patients:
S&P analyst's remarks on May 1: ".We remain
confident in VRTX's cystic fibrosis program, with key F508del mutation sub-group
on track for '14 FDA filing. "
Count on expdited approval by the FDA in 2014 to treat close to twenty thousand CF patients in the US alone. That's multibillion dollar a year market. so 300 million of lost Incivek revenue won't be a huge problem going forward, and VX 135 will likely generate far more in the years to come. Then factor in the poetential for VX 509, 787, 661 983, and the second gneration correctors for treating the 508d heterozygotes with CF, and the future for Vertex is amazing.
Q, I agree. Although am somewhat disappointed that there has been very little from vertex on doing anything with 787 and 509. They are too big for vertex to own the trials and they pretty much said that while the molecules look good, they need to partner to move them along. That was quite a while ago and it has been crickets since. Also, I knew 222 was dead. They had not mentioned it for a while and finally took the write down last quarter. When they don't mention anything for a while it is a bad sign.